Advertisement

Cytokines and Cytokine Antagonists in Sepsis and Critical Illness

  • S. F. Lowry
  • L. L. Moldawer
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1992)

Abstract

Mediators of the cytokine class are widely assumed to exert significant pathophysiological influences in septic and critically ill patients [1]. Among the cytokines exhibiting significant proinflammatory characteristics, tumor necrosis factor (TNF) and interleukin-1 (IL-1) appear to be the most promising candidate mediators for promoting both the acute septic responses and the organ failure sequelae of sepsis. However, several prospective studies seeking to determine the incidence of circulating TNF and IL-1 in critically ill patients have failed to consistently detect these cytokines during clinical conditions consistent with their known biological functions [2, 3].

Keywords

Critical Illness Tumor Necrosis Factor Production Soluble Tumor Necrosis Factor Receptor Endotoxin Administration Tumor Necrosis Factor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fong Y, Moldawer LL, Shires GT, Lowry SF (1990) The biological characteristics of cyto-kines and their implication in surgical injury. Surg Gynecol Obstet 170:363–378PubMedGoogle Scholar
  2. 2.
    Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489–494PubMedCrossRefGoogle Scholar
  3. 3.
    Marano MA, Fong Y, Moldawer LL, et al. (1990) Serum Cachectin/TNF in critically ill burn patients correlates with infection and mortality. Surg Gynecol Obstet 170:32–38PubMedGoogle Scholar
  4. 4.
    Calandra T, Baumgartner JD, Grau GE, et al. (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-y in the serum of patients with septic shock. J Infect Dis 161:982–987PubMedCrossRefGoogle Scholar
  5. 5.
    Fong Y, Marano MA, Moldawer LL, et al. (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in man. J Clin Invest 85:1896–1904PubMedCrossRefGoogle Scholar
  6. 6.
    Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53:45–63PubMedCrossRefGoogle Scholar
  7. 7.
    Keogh CV, Fong Y, Barber A, et al. (1990) Identification of a novel cell-associated murine tumor necrosis factor. Arch Surg 125:79–85PubMedCrossRefGoogle Scholar
  8. 8.
    Auron PE, Warner SJ, Webb AD, et al. (1987) Studies on the molecular nature of human interleukin 1. J Immunol 138:1447–1456PubMedGoogle Scholar
  9. 9.
    van der Poll T, Biiller HR, ten Cate H, et al. (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. New Engl J Med 322:1622–1627PubMedCrossRefGoogle Scholar
  10. 10.
    Starnes HF Jr, Warren RA, Jeevanandam M, et al. (1988) Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 82:1321–1325PubMedCrossRefGoogle Scholar
  11. 11.
    Michie HR, Spriggs DR, Manogue KR, et al. (1988) Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280–286PubMedGoogle Scholar
  12. 12.
    Tewari A, Buhles WC, Starnes HF (1990) Effects of interleukin-1 on platelet counts. Lancet 2:712–714CrossRefGoogle Scholar
  13. 13.
    Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–552PubMedCrossRefGoogle Scholar
  14. 14.
    Fischer E, Marano MA, Barber A, et al. (1991) Interleukin-la administration can replicate the hemodynamic and metabolic responses to sublethal endotoxemia. Am J Physiol 261:442–452Google Scholar
  15. 15.
    Dinarello CA (1991) The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163:1177–1184PubMedCrossRefGoogle Scholar
  16. 16.
    Fong Y, Tracey KJ, Moldawer LL, et al. (1989) Antibodies of cachectin/TNF reduce interleukin-lβ and interleukin-6 appearance during lethal bacteremia. J Exp Med 170:1627–1633PubMedCrossRefGoogle Scholar
  17. 17.
    Hesse DG, Tracey KJ, Fong Y, et al. (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147–153PubMedGoogle Scholar
  18. 18.
    VanZee KJ, De Forge LE, Fischer E, et al. (1991) Interleukin-8 circulates during septic shock, endotoxemia, and following interleukin-1 administration. J Immunol 146:3478–3482PubMedGoogle Scholar
  19. 19.
    Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA (1990) Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40–47PubMedGoogle Scholar
  20. 20.
    LaMarre J, Wollenberg GK, Gonias SL, Hayes MA (1991) Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest 65:3–14Google Scholar
  21. 21.
    Warren RS, Starnes HF Jr., Gabrilove JL, Oettgen HF, Brennan MF (1987) The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 122:1396–1400PubMedCrossRefGoogle Scholar
  22. 22.
    van der Poll T, Romijn JA, Endert E, Borm JJ, Büller HR, Sauerwein HP (1991) Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 261:457–465Google Scholar
  23. 23.
    Tracey KJ, Fong Y, Hesse DG, et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664PubMedCrossRefGoogle Scholar
  24. 24.
    Beutler B, Krochnin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: Mechanisms for endotoxin resistance. Science 232:977–980PubMedCrossRefGoogle Scholar
  25. 25.
    Barber AE, Coyle SM, Fong Y, et al. (1990) Impact of hypercortisolemia on the metabolic and hormonal responses to endotoxin in man. Surg Forum 41:74–77Google Scholar
  26. 26.
    Spinas GA, Bloesch D, Kaufmann MT, Keller U, Dayer JM (1990) Induction of plasma inhibitors of interleukin 1 and TNF-α activity by endotoxin administration to normal humans. Am J Physiol 234:993–997Google Scholar
  27. 27.
    Engelmann H, Novick D, Wallach D (1990) Two tumor necrosis factor-binding proteins purified from human urine. J Bio Chem 265:1531–1536Google Scholar
  28. 28.
    Kohno T, Brewer MT, Baker SL, et al. (1990) A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci 87:8331–8335PubMedCrossRefGoogle Scholar
  29. 29.
    Lesslauer W, Tabuchi H, Gentz R, et al. (1992) Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality. Eur J Immunol (in press)Google Scholar
  30. 30.
    Eisenberg SP, Evans RJ, Arend WP, et al. (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341–346PubMedCrossRefGoogle Scholar
  31. 31.
    Michie HR, Manogue KR, Spriggs DR, et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486PubMedCrossRefGoogle Scholar
  32. 32.
    Richardson RP, Rhyne CD, Fong Y, et al. (1989) Peripheral blood leukocyte kinetics following in vivo Lipopolysaccharide (LPS) administration to normal human subjects: Influence of elicited hormones and cytokines. Ann Surg 210:239–245PubMedCrossRefGoogle Scholar
  33. 33.
    Calvano SE, Barber AE, Hawes AS, de Riesthal HF, Coyle SM, Lowry SF (1992) Effect of combined cortisol-endotoxin (LPS) administration on peripheral blood leukocyte numbers and phenotype in normal humans. Arch Surg (in press)Google Scholar
  34. 34.
    Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: Pathogenesis. Lancet 2:732–735CrossRefGoogle Scholar
  35. 35.
    Luger A, Graf H, Schwarz HP, Stummvoll HK, Luger TA (1986) Decreased serum interleukin-1 activity and monocyte interleukin-1 production in patients with fatal sepsis. Crit Care Med 14:458–461PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • S. F. Lowry
  • L. L. Moldawer

There are no affiliations available

Personalised recommendations